Bonnar 1996.

Methods	Randomised controlled trial, parallel group, no evidence of blinding, randomisation by computer‐generated randomisation list 5 women withdrew during first cycle of treatment (2 from MFA group, 2 from ethamsylate group and 1 from tranexamic acid group) ITT analysis on remaining 76 women (18 of whom withdrew during the study) Power calculation for sample size made No loss to follow‐up
Participants	Dublin, Ireland 81 women, mean age 39 years (range 35–46 years) with a mean MBL > 80 mL/cycle measured over 3 consecutive menstrual periods. Exclusions: "Organic" causes of menorrhagia by gynaecological investigation (hysteroscopy, endometrial biopsy and cervical smear). History of renal or hepatic impairment, previous thromboembolic disease, inflammatory bowel disease, peptic or intestinal ulceration or coagulation or fibrinolytic disorders
Interventions	Group 1: tranexamic acid: 1 g 4 times daily for 5 days from day 1 of menses, n = 26 Group 2: ethamsylate: 500 mg 4 times daily for 5 days from day 1 of menses, n = 27 Group 3: MFA: 500 mg 3 times daily for 5 days from day 1 of menses, n = 23 Duration: 3 menstrual cycles
Outcomes	MBL (by alkaline haematin method) Duration of bleeding (days) Patient's estimation of blood loss (less, same, greater) Quality of life (dysmenorrhoea) Adverse events (type, incidence) Patient acceptability of treatment (would you be prepared to continue with this treatment?)
Notes	No ITT analysis Baseline comparability done Additional data provided by the author
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated list
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding (performance bias and detection bias) All outcomes	High risk	No blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	5/81 women withdrew (2 from MFA group, 2 from ethamsylate group and 1 from tranexamic acid group)
Other bias	Low risk	Groups similar at baseline